Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus MEPIVACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus MEPIVACAINE HYDROCHLORIDE.
ALCAINE vs MEPIVACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Mepivacaine hydrochloride is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by binding to sodium channels in the neuronal cell membrane, thereby stabilizing the membrane and preventing depolarization.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
1-2% solution, 5-20 mL local infiltration or nerve block, maximum 400 mg per procedure.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours). In neonates and patients with hepatic dysfunction, half-life may be prolonged up to 8–10 hours.
Renal excretion of parent drug and metabolites: <5% unchanged.
Primarily hepatic metabolism via amidase enzymes; ~95% excreted as metabolites in bile and feces, <5% unchanged in urine.
Category C
Category C
Local Anesthetic
Local Anesthetic